Felicia Gomez
Has grant
Assistant Professor (tenure track)
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Characterizing the Expression Profile of Hodgkin Lymphoma Using Single Nuclei RNA Sequencing
Open Date: 2025-01-01
Close Date: 2025-12-31
Grant: Close
Deep Sequencing of Relapse and Refractory Hodgkin Lymphoma Genomes: A Study of Tumor Biology and Evolution
Open Date: 2023-09-01
Close Date: 2026-08-31
Grant: Close
Doctoral Dissertation Improvement: Patterns of Genetic Diversity and Signatures of Natural Selection at the Intercellular Adhesion Molecule-1 (ICAM-1) and CD36 Loci
Open Date: 2009-09-01
Close Date: 2010-08-31
Articles (7)
Year:
2026
Regulating Hippo. A, Diagram of pathways that regulate Hippo signaling. Identified SMGs are shown in red; genes mutated in at least one non-hypermutated sample are shown in yellow; genes only mutated in the hypermutated sample (HL-513) are shown in orange. The gene mutation frequency across the cohort is shown as a percent. The pathways labeled in green indicate larger pathways not shown in this diagram. B, The total number and type of mutation observed are shown in the inset bar chart. C, Lolliplot of CDH5 ; mutations identified in the current study are shown on the top and COSMIC mutations found in lymphoid tissue on the bottom. D, Lolliplot of mutations identified at GNA13 ; mutations identified in the current study are shown on the top and COSMIC mutations found in lymphoid tissue on the bottom.
Year:
2025
The malignant Hodgkin and Reed Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) are scarce in affected lymph nodes, creating a challenge to detect driver somatic mutations. As an alternative to cell purification techniques, we hypothesized that ultra-deep exome sequencing would allow genomic study of HRS cells, thereby streamlining analysis and avoiding technical pitfalls. To test this, 31 cHL tumor/normal pairs were exome sequenced to approximately 1,000× median depth of coverage. An orthogonal error-corrected sequencing approach verified >95% of the discovered mutations. We identified mutations in genes novel to cHL including: CDH5 and PCDH7, novel stop gain mutations in IL4R , and a novel pattern of recurrent mutations in pathways regulating Hippo signaling. As a further application of our exome sequencing, we attempted to identify expressed somatic single-nucleotide variants (SNV) in single-nuclei RNA sequencing (snRNA-seq) data generated from a patient in our cohort. Our snRNA analysis identified a clear cluster of cells containing a somatic SNV identified in our deep exome data. This cluster has differentially expressed genes that are consistent with genes known to be dysregulated in HRS cells (e.g., PIM1 and PIM3 ). The cluster also contains cells with an expanded B-cell clonotype further supporting a malignant phenotype. This study provides proof-of-principle that ultra-deep exome sequencing can be utilized to identify recurrent mutations in HRS cells and demonstrates the feasibility of snRNA-seq in the context of cHL. These studies provide the foundation for the further analysis of genomic variants in large cohorts of patients with cHL. Significance: Our data demonstrate the utility of ultra-deep exome sequencing in uncovering somatic variants in Hodgkin lymphoma, creating new opportunities to define the genes that are recurrently mutated in this disease. We also show for the first time the successful application of snRNA-seq in Hodgkin lymphoma and describe the expression profile of a putative cluster of HRS cells in a single patient.
Year:
2025
Personalized cancer vaccines designed to target neoantigens represent a promising new treatment paradigm in oncology. In contrast to classical idiotype vaccines, we hypothesized that “polyvalent” vaccines could be engineered for the personalized treatment of follicular lymphoma (FL) using neoantigen discovery by combined whole-exome sequencing (WES) and RNA sequencing (RNA-seq). Fifty-eight tumor samples from 57 patients with FL underwent WES and RNA-seq. Somatic and B-cell clonotype neoantigens were predicted and filtered to identify high-quality neoantigens. B-cell clonality was determined by the alignment of B-cell receptor (BCR) CDR3 regions from RNA-seq data, grouping at the protein level, and comparison with the BCR repertoire from healthy individuals using RNA-seq data. An average of 52 somatic mutations per patient (range, 2-172) were identified, and ≥2 (median, 15) high-quality neoantigens were predicted for 56 of 58 FL samples. The predicted neoantigen peptides were composed of missense mutations (77%), indels (9%), gene fusions (3%), and BCR sequences (11%). Building off of these preclinical analyses, we initiated a pilot clinical trial using personalized neoantigen vaccination combined with PD-1 blockade in patients with relapsed or refractory FL (#NCT03121677). Synthetic long peptide vaccines targeting predicted high-quality neoantigens were successfully synthesized for and administered to all 4 patients enrolled. Initial results demonstrate feasibility, safety, and potential immunologic and clinical responses. Our study suggests that a genomics-driven personalized cancer vaccine strategy is feasible for patients with FL, and this may overcome prior challenges in the field. This trial was registered at www.ClinicalTrials.gov as #NCT03121677.
Year:
2024
People diagnosed with cancer and their formal and informal caregivers are increasingly faced with a deluge of complex information, thanks to rapid advancements in the type and volume of diagnostic, prognostic, and treatment data. This commentary discusses the opportunities and challenges that the society faces as we integrate large volumes of data into regular cancer care.
Year:
2024
Year:
2023
Year:
2023
Collaborators (14)
Robert Fulton
Assistant Professor
Washington University in St. Louis
Todd A. Fehniger
Professor
Washington University School of Medicine
Obi Griffith
Professor
Washington University in St. Louis
Jayashree Kalpathy-Cramer
Professor
University of Colorado School of Medicine
Kilannin Krysiak
Associate Professor
Washington University in St. Louis
Nancy Bartlett
Koman Professor of Medical Oncology in Medicine
Washington University in St. Louis
Susanna Kiwala
Washington University in St. Louis
David A. Russler-Germain
Washington University School of Medicine
Zachary Skidmore
Senior Scientist
Washington University in St. Louis
Eric J. Duncavage
Professor/Director of Molecular Oncology
Washington University School of Medicine
Malachi Griffith
Professor
Washington University in St. Louis
Christopher Miller
Associate Professor
Washington University in St. Louis
Meliha Yetisgen
Professor
University of Washington
Neha Mehta-Shah
Washington University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.